Abstract
Objective The objective of this study is to investigate how lymphoid progenitor mechanisms contribute to the leukemogenesis in Acute Lymphoblastic Leukemia.
Background Acute Lymphoblastic Leukemia (ALL), the leading childhood cancer, remains challenging despite treatment advances. ALL originates from aberrant clonal expansion of immature lymphoid progenitor cells (LPCs) due to genetic abnormalities. This study looks into LPC genetic dysregulations, aiming to identify therapeutic targets and enhance prognostic stratification. Understanding ALL pathogenesis not only improves outcomes but also informs broader cancer research, offering potential insights for hematologic malignancies and oncogenesis, promising advancements in clinical practice.
Methods Databases, including PubMed, MEDLINE, Google Scholar, and open access/subscription-based journals were searched for published articles without any date restrictions, to investigate leukemogenesis in acute lymphoblastic leukemia and the impact of down syndrome through the developmental regulators of lymphoid progenitor cells. Based on the criteria mentioned in the methods section, studies were systematically reviewed to investigate ALL leukemogenesis. This study adheres to relevant PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).
Results Acute Lymphoblastic Leukemia (ALL) development is marked by dysregulations in key factors governing Lymphoid Progenitor Cells (LPCs) proliferation and differentiation. Dysregulations include upregulation of transcription factors Ikaros and PU.1, along with heightened expression of surface markers CD34 and CD38. Increased levels of signaling molecules IL-7, SCF, and FLT3 Ligand drive LPC proliferation, while alterations in epigenetic modifiers DNMTs, HDACs, and HATs further contribute to uncontrolled cell division. Dysregulated transcription factors Ikaros, PU.1, E2A (TCF3), EBF1, and Notch1 disrupt LPC differentiation pathways, alongside aberrant expression of surface markers CD10, CD7, and CD45RA. Dysregulated signaling through IL-7 and the Notch pathway, along with epigenetic modifications mediated by DNMTs, HDACs, and HATs, collectively create a conducive landscape for ALL development.
Conclusion This study into the origins of ALL investigates the roles of transcription factors, surface markers, signaling molecules, and epigenetic modifiers in LPC proliferation and differentiation. Dysregulation of these components, often due to mutations in genes like GATA1, CRLF2, JAK2, and RAS, disrupts normal hematopoietic development and leads to leukemic transformation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
I declare that there was not any source of funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors have read and approved the manuscript.
Data Availability statement
All data generated or analyzed during this study are included in this article.
Abbreviations
- NF-κB
- Nuclear Factor-kappa B
- ALL
- Acute Lymphoblastic Leukemia
- LPCs
- Lymphoid Progenitor Cells
- PU.1
- Purine-rich Box-1
- E2A (TCF3)
- Transcription Factor 3
- EBF1
- Early B-cell Factor 1
- SCF
- Stem Cell Factor
- FLT3
- Fms-like Tyrosine Kinase 3
- IL-7
- Interleukin-7
- Ikaros
- IKAROS family zinc finger 1
- CD34
- Cluster of Differentiation 34
- CD38
- Cluster of Differentiation 38
- CD10
- Cluster of Differentiation 10
- CD7
- Cluster of Differentiation 7
- CD45RA
- Cluster of Differentiation 45RA
- Notch1
- Neurogenic locus notch homolog protein 1
- CRLF2
- Cytokine Receptor-like Factor 2
- JAK2
- Janus Kinase 2
- RAS
- Rat Sarcoma Virus Oncogene
